Forum Topic News
  • Conversation: Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease:

    • November 6, 2018 6:52 PM GMT
    • Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease:


      Amgen and Provention Bio, Inc., a clinical-stage biopharmaceutical company focused on immune-mediated diseases, today announced a licensing and co-development agreement for AMG 714, identified by Provention as PRV-015. AMG 714 is a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease (NRCD). Development efforts at Provention will be led by researchers with previous experience developing AMG 714.
      Under the terms of the agreement, Provention will conduct and fund a Phase 2b trial in NRCD and lead the next phase of development and regulatory activities for the program. Amgen will make a $20 million investment coincident with Provention's next financing event, subject to certain terms and conditions.
      Full details: https://prn.to/2Dtly4i

Add Reputation

Do you want to add reputation for this member by this post?

or cancel
‚Äč